Generic Name and Formulations:
Silver sulfadiazine 1%; cream.
Indications for SILVADENE:
Prophylaxis and treatment of sepsis in 2nd and 3rd degree burns.
Apply 1–2 times daily aseptically to approximately 1/16 inch depth to cleansed and debrided burns. Reapply promptly if removed. Continue until wound closed.
Premature infants. Within first 2 months of birth. Late pregnancy.
G6PD deficiency. Impaired renal or hepatic function. Monitor serum sulfa levels and renal function in extensive burns. Avoid eyes. Pregnancy (Cat.B). Nursing mothers: not recommended.
Leukopenia increased with concomitant cimetidine. May inactivate debriding enzymes.
Transient leukopenia, skin necrosis, erythema multiforme, skin discoloration, burning sensation, rash, pruritus, interstitial nephritis, reduction in bacterial growth; systemic sulfonamide reactions, fungal overgrowth.
Crm—20g, 50g, 85g, 400g, 1000g
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline